We performed mutagenesis on the HR2 domain and tested the activity of the lead compounds against the EBOV mutants to identify which HR2 residues interacted with the lead compounds. Briefly, each HR2 residue (residues 610 to 636) was separately replaced with alanine (A) by site-directed mutagenesis (Agilent Technologies) and confirmed by sequencing (BGI, Beijing, China). The resulting plasmids were used to package the EBOV mutants. The infectivity of the EBOV mutants and the antiviral activity against them were evaluated as described above. The HR2 domain from influenza virus was mapped in the same manner by using amino acid substitutions.

注意:以上内容是从某篇研究文章中自动提取的,可能无法正确显示。



Q&A
请登录并在线提交您的问题
您的问题将发布在Bio-101网站上。我们会将您的问题发送给本研究方案的作者和具有相关研究经验的Bio-protocol成员。我们将通过您的Bio-protocol帐户绑定邮箱进行消息通知。